Evidence map›Paper›PMID 35932909›Full record

ArticlePeptides2022

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.

Terry W Moody, Irene Ramos-Alvarez, Robert T Jensen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Peptides, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Terry W MoodyDepartment of Health and Human Services, National Institutes of Health, National Cancer Institute, Center for Cancer Training, Bethesda, MD 20892, USA. Electronic address: moodyt@bprb.nci.nih.gov.
Irene Ramos-AlvarezNational Institute of Diabetes, Digestive and Kidney Disease, Digestive Diseases Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.
Robert T JensenNational Institute of Diabetes, Digestive and Kidney Disease, Digestive Diseases Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA.
National Institute of Diabetes and Digestive and Kidney Diseases · USNational Cancer Institute · US

Funding

Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factorsZIADK053101 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JENSEN, ROBERT · 2009 to 2025
$12.9M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Neurotensin (NTS) receptor 1 regulates the growth non-small cell lung cancer (NSCLC) cells. NTS binds with high affinity to NTSR1, leading to increased tyrosine phosphorylation of the EGFR and HER2. Using Calu3, NCI-H358, or NCI-H441 cells, the effects of NTS on HER3 transactivation were investigated. HER3 tyrosine phosphorylation was increased by NTS or neuregulin (NRG1) addition to NSCLC cells. NCI-H358, NCI-H441, and Calu-3 cells have HER3, NTSR1 and neuregulin (NRG)1 protein. NTSR1 regulation of HER3 transactivation was impaired by SR48692 (NTSR1 antagonist) or monoclonal antibody (mAb)3481 (HER3 blocker). Immunoprecipitation experiments indicated that NTS addition to NCI-H441cells resulted in the formation of EGFR/HER3 and HER2/HER3 heterodimers. The ability of NTS to increase HER3 tyrosine phosphorylation was impaired by GM6001 (MMP inhibitor), PP2 (Src inhibitor), Tiron (superoxide scavenger), or N-acetylcysteine (antioxidant). Adding NTS to NSCLC cells increased phosphorylation of ERK, HER3, and AKT. NTS or NRG1 increased colony formation of NSCLC cells which was strongly inhibited by SR48692 and mAb3481. The results indicate that NTSR1 regulates HER3 transactivation in NSCLC cells leading to increased proliferation.

Indexed as

Carcinoma, Non-Small-Cell LungLung Neoplasms1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltAcetylcysteineAntibodies, MonoclonalAntioxidantsCell Line, TumorCell ProliferationErbB ReceptorsHumansMatrix Metalloproteinase InhibitorsNeuregulinsNeurotensinPhosphorylationProto-Oncogene Proteins c-aktReceptor, ErbB-31,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltAcetylcysteineAntibodies, MonoclonalAntioxidantsERBB3 protein, humanErbB ReceptorsMatrix Metalloproteinase InhibitorsNeuregulinsNeurotensinneurotensin type 1 receptorProto-Oncogene Proteins c-aktReceptor, ErbB-3Receptors, NeurotensinSuperoxidesTyrosineHER3Lung cancerNeuregulin 1NeurotensinPhosphorylationSignal transduction

Identifiers

PMID35932909
PMCPMC9529830
OpenAlexW4289598130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.